SELLAS Life Sciences Group, Inc.

SLS | $1.33 -0.75% -1.52% 0

(0.0% 1d) (26.7% 1m) (-19.9% 1y) (0.0% 2d) (0.0% 3d) (-4.3% 7d) (-27.18% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 74,836,001
http://www.sellaslifesciences.com
Sec Filling | Patents | 5 employees

(US) SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and ct-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

cancer

add to watch list Paper trade email alert is off

Press-releases

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| Email alert Add to watchlist
life year update sciences financial results

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 29.13% | O: -0.97% H: 1.18% C: -0.98%
gfh009 brukinsa cell collaboration trial therapy study

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 27.88% | O: 1.92% H: 2.83% C: 0.0%
sls009 positive update topline aml study

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Published: 2024-03-19 (Crawled : 20:00) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 26.67% | O: 2.86% H: 1.85% C: -3.7%
nasdaq life million direct group offering sciences

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 26.67% | O: 6.67% H: 0.89% C: -6.25%
life update sciences

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| -14.19% | O: -21.29% H: 0.0% C: -9.84%
nasdaq life million direct group offering sciences

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
Published: 2024-03-08 (Crawled : 13:00) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 1.53% | O: -0.76% H: 4.62% C: -3.08%
commercialization

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
Published: 2024-03-01 (Crawled : 13:30) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 31.68% | O: -0.99% H: 4.0% C: 0.0%
sls009 conference life presentation sciences leukemia

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 31.68% | O: 4.95% H: 0.0% C: -4.72%
sls009 life sciences leukemia

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
Published: 2024-02-06 (Crawled : 13:30) - globenewswire.com
SLS | $1.33 -0.75% -1.52% 0

Health Technology

| 119.73% | O: 0.45% H: 13.49% C: 11.74%
sls009 publication preclinical

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001104659-24-006410	4	2024-01-25	2024-01-22	Buy	A	238500	238500
0001104659-24-006410	4	2024-01-25	2024-01-22	Buy	A	159000	376421
0001104659-24-006407	4	2024-01-25	2024-01-22	Buy	A	10000	10000
0001104659-24-006407	4	2024-01-25	2024-01-22	Buy	A	6000	10582
0001104659-24-006405	4	2024-01-25	2024-01-22	Buy	A	50000	50000
0001104659-24-006405	4	2024-01-25	2024-01-22	Buy	A	35000	117225